Dalnicastobart clinical trials
Also written LVGN7409.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses dalnicastobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LVGN7409
- 2
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Lyvgen Biopharma Holdings Limited (2) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Pradusinstobart (1) · Exlinkibart (1)
Studies
Open first, then newest update. How each study uses dalnicastobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsTerminatedPhase 1M.D. Anderson Cancer CenterNCT05075993Written as LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
- Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic MalignancyCompletedPhase 1Lyvgen Biopharma Holdings LimitedNCT04635995Written as LVGN7409
- Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory MalignancyCompletedPhase 1Lyvgen Biopharma Holdings LimitedNCT05152212Written as LVGN7409
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
Codes
What other systems call dalnicastobart · ClinicalTrials.gg INT014350
- UNII (FDA) 1SN6KFW31LDALNICASTOBARTOne source FDA
- NCI Thesaurus C178278DalnicastobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1SN6KFW31L | DALNICASTOBART | One source FDA |
| NCI Thesaurus | C178278 | Dalnicastobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.